Archive for December 2nd, 2011

NPSP files NDA short bowel syndrome + CLDX CLSN AVEO ANTH IDRA ANX

Dec 02, 2011 No Comments by

Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced that it has launched a pivotal, randomized, double-blind, controlled Phase 3 trial of rindopepimut in patients with surgically resected epidermal growth factor variant III (EGFRvIII)-positive glioblastoma, the “ACT IV Study.” Celsion Corporation (NASDAQ: CLSN) today announced that it has received commitments from investors to purchase an aggregate of […]

Daily News Read more